Streetbeat News

ACON

Aclarion, Inc.

https://www.aclarion.com

Industry

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Top Wall Street analysts have updated their price targets and ratings for several companies. Notable changes include Needham cutting Micron's target to $140, Ascendiant Capital lowering Aclarion's target to $1.5, and Gordon Haskett upgrading Ollie's Bargain Outlet to Buy. Baird raised Foot Locker's target to $35 and Peloton's to $4.75. Loop Capital cut Baidu's target to $115, while JP Morgan upgraded BJ's Wholesale to Neutral. Baird boosted SentinelOne's target to $29, and Wells Fargo upgraded American Homes 4 Rent and Camden Property Trust.

Portfolio Pulse from Avi Kapoor

August 26, 2024 | 12:32 pm

Ascendiant Capital has maintained a Buy rating on Aclarion (NASDAQ:ACON) but has lowered the price target from $1.6 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 9:50 am

Aclarion, Inc. has launched the CLUE Trial to assess how often Nociscan's AI-generated biomarker data influences changes in surgical treatment plans for chronic low back pain. This trial will involve multiple physicians and sites, contributing to Aclarion's clinical evidence.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:02 pm

Aclarion, Inc. (NASDAQ: ACON) has announced a commercial agreement with Sheridan Community Hospital in Michigan, making it the first healthcare institution in the state to adopt Nociscan. This agreement will expand access to Nociscan for John Keller, MD, a leading neurosurgeon and Aclarion Medical Advisor, and his patients in central Michigan.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:20 pm

Aclarion has secured payer coverage for its Nociscan technology from Vitality, making it now covered by three of the four largest private health insurers in the UK. This means nearly 60% of private health insurance patients in Greater London now have access to Nociscan.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 1:09 pm

Ascendiant Capital has initiated coverage on Aclarion (NASDAQ:ACON) with a Buy rating and set a price target of $1.6.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:30 am

Aclarion has been granted European patent EP3928695 for a system and method using Magnetic Resonance Spectroscopy to diagnose back pain, including low back pain associated with Degenerative Disc Disease.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 7:59 pm

Aclarion has announced that AXA will provide initial payer coverage for its Nociscan technology. This development marks a significant milestone for Aclarion as it could lead to increased adoption and revenue growth.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:31 pm

Aclarion shares are trading higher following the announcement of an expanded commercial engagement with The London Clinic for Nociscan.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:32 pm

Aclarion announced that the payment for each Nociscan is being increased from the original contract.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.